Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer

[1]  E. Estey,et al.  Phase I trial of alpha-particle immunotherapy with 225Ac-lintuzumab and low-dose cytarabine in patients age 60 or older with untreated acute myeloid leukemia. , 2017 .

[2]  J. E. Mattson,et al.  A Radium-223 microgenerator from cyclotron-produced trace Actinium-227. , 2017, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[3]  S. Larson,et al.  Internalization of secreted antigen–targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis , 2016, Science Translational Medicine.

[4]  F. Saad,et al.  Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. , 2016, The Lancet. Oncology.

[5]  S. Koochekpour,et al.  Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer , 2016, Oncotarget.

[6]  F. Mottaghy,et al.  225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[7]  T. Tran,et al.  Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2 , 2016, EJNMMI Research.

[8]  R. Baum,et al.  177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy , 2016, The Journal of Nuclear Medicine.

[9]  M. Doucet,et al.  Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis , 2015, Journal of the National Cancer Institute.

[10]  D. Tindall,et al.  Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. , 2015, Cancer research.

[11]  H. Lilja,et al.  Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6 , 2014, EJNMMI Research.

[12]  C. Livi,et al.  Analysis of Prostate-Specific Antigen Transcripts in Chimpanzees, Cynomolgus Monkeys, Baboons, and African Green Monkeys , 2014, PloS one.

[13]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[14]  F. Feng,et al.  A hormone-DNA repair circuit governs the response to genotoxic insult. , 2013, Cancer discovery.

[15]  H. Hieronymus,et al.  Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.

[16]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[17]  S. Larson,et al.  Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. , 2012, Cancer discovery.

[18]  Max E Valentinuzzi,et al.  SAFETY AND EFFICACY , 2010 .

[19]  D. Troyer,et al.  Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases , 2008, The Prostate.

[20]  D. Scheinberg,et al.  Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[22]  D. Scheinberg,et al.  Design and synthesis of 225Ac radioimmunopharmaceuticals. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[23]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[24]  D. Scheinberg,et al.  Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.

[25]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[26]  H. Lilja,et al.  Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. , 1999, European journal of biochemistry.

[27]  D. Scheinberg,et al.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  E. Ward,et al.  Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. , 1997, Journal of immunology.

[29]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.